Difference between revisions of "Week4"
| Line 35: | Line 35: | ||
*Abstract | *Abstract | ||
| + | Background: The APOE {varepsilon}4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE {varepsilon}4 allele, those who are heterozygous for the allele, and noncarriers is unknown. | ||
| + | |||
| + | Methods: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE {varepsilon}4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE {varepsilon}4 allele, using a mixed model for longitudinal change with age. | ||
| + | |||
| + | Results: We analyzed 815 subjects: 317 APOE {varepsilon}4 carriers (79 who were homozygous for the APOE {varepsilon}4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele–dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status. | ||
| + | |||
| + | Conclusions: Age-related memory decline in APOE {varepsilon}4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status. | ||
*Keywords | *Keywords | ||
Revision as of 18:29, 13 January 2010
Back to NS210b Class page
Contents
MANUSCRIPT ID
- Title
- Reference
- Abstract
- Keywords
- Input Author
MANUSCRIPT DETAILS
- Introduction/Aims
- Methods
- Results
- Summary
- Discussion
MANUSCRIPT ID
- Title
- Reference
- Abstract
Background: The APOE {varepsilon}4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE {varepsilon}4 allele, those who are heterozygous for the allele, and noncarriers is unknown.
Methods: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE {varepsilon}4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE {varepsilon}4 allele, using a mixed model for longitudinal change with age.
Results: We analyzed 815 subjects: 317 APOE {varepsilon}4 carriers (79 who were homozygous for the APOE {varepsilon}4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele–dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status.
Conclusions: Age-related memory decline in APOE {varepsilon}4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.
- Keywords
- Input Author
MANUSCRIPT DETAILS
- Introduction/Aims
- Methods
- Results
- Summary
- Discussion
INFORMATICS: GenBank
GenBank is an open-access database of annotated sequences of DNA, mRNA, and the corresponding proteins. One can add [1] to the database, submitting sequences, further annotations, and corrections. Alternatively (and likely more usefully), one can search GenBank. Searches are conducted via Entrez Nucleotide [2].
